ESMO Congress: Lung Cancer

EIK1001 plus pembrolizumab and chemo showed a 64% ORR and manageable safety in first-line stage IV NSCLC, per phase 2 TeLuRide-005 data.

Long-term data from the ALINA trail continued to support the use of adjuvant alectinib in resected, ALK-positive, early stage non–small cell lung cancer.

Xiuning Le, MD, PhD, discusses findings from the phase 1/2 SOHO-01 trial evaluating sevabertinib monotherapy in HER2-mutant advanced NSCLC.

Pasi A. Jänne, MD, PhD, discusses OS outcomes with osimertinib with or without chemotherapy based on baseline prognostic factors in EGFR-mutant NSCLC.

Pembrolizumab before and after surgery reduced the risk of death compared with placebo for patients with early-stage non–small cell lung cancer.

Ivonescimab plus chemotherapy improved PFS and response rates vs tislelizumab in advanced squamous NSCLC, with a manageable safety profile.

Sacituzumab tirumotecan reduced the risk of progression or death by 51% in nonsquamous EGFR-mutated NSCLC resistant to EGFR TKIs.

Zipalertinib demonstrated preliminary efficacy and low rates of treatment-related dose reductions and discontinuations in NSCLC harboring EGFR mutations and CNS metastases and/or leptomeningeal disease.

Durvalumab in combination with chemotherapy produced outcomes consistent with prior studies in patients with advanced pleural mesothelioma.

The SKYSCRAPER-03 trial missed the end point of a PFS benefit with tiragolumab plus atezolizumab vs durvalumab consolidation in advanced NSCLC.

First-line treatment with tarlatamab plus chemoimmunotherapy and anti–PD-L1 maintenance therapy generated durable responses in patients with ES-SCLC.

Osimertinib plus chemotherapy improved OS vs osimertinib alone in EGFR-mutated advanced non–small lung cancer, irrespective of poor prognostic factors.

NorthStar findings support osimertinib plus local consolidative therapy in EGFR-mutant non–small cell lung cancer.

Sevabertinib monotherapy led to robust and durable responses in first-line and pretreated patients with HER2-mutant advanced non–small cell lung cancer.

First-line alectinib produced a clinically meaningful overall survival benefit in advanced ALK-positive non–small cell lung cancer.

Zongertinib was effective for the first-line treatment of patients with treatment-naive HER2-mutated NSCLC.

Tony S.K. Mok, BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO, shares final OS data from the phase 3 ALEX study in ALK-positive NSCLC.

Ahead of the 2025 ESMO Congress, OncLive spoke with experts in lung cancer care to preview the most anticipated meeting abstracts.

OncLive social media polls reveal which lung cancer abstracts are generating excitement ahead of the 2025 ESMO Congress.

Vote in OncLive's polls to share which lung and genitournary cancer abstracts you're most anticipating at the 2025 ESMO Congress.

Durvalumab plus monalizumab and durvalumab plus ceralasertib showed promising long-term benefits in advanced NSCLC.

Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses OS data with amivantamab plus chemotherapy in EGFR-mutated, advanced NSCLC after progression on osimertinib.

Perioperative nivolumab extended event-free survival vs placebo in patients with resectable non–small cell lung cancer.

TORL-1-23 was safe and active in heavily pretreated, Claudin-6–positive advanced solid tumors, including platinum-resistant ovarian cancer.

The benefits of adagrasib over docetaxel were seen regardless of baseline brain metastases, according to findings presented at ESMO.

Zipalertinib demonstrates safety and efficacy in heavily pretreated patients with NSCLC EGFR exon 20 insertion mutations who progressed on or after amivantamab.

The combination of encorafenib and binimetinib showed anti-tumor responses in treatment-naïve BRAF V600E-mutant advanced non–small cell lung cancer.

A lower dose of pembrolizumab may be as effective as the standard dose for treating stage IV non-small cell lung cancer.